l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review

被引:0
作者
María Tosta Pérez
Lisandra Herrera Belén
Pablo Letelier
Yolanda Calle
Adalberto Pessoa
Jorge G. Farías
机构
[1] Universidad de La Frontera,Department of Chemical Engineering, Faculty of Engineering and Science
[2] Universidad Santo Tomas,Departamento de Ciencias Básicas, Facultad de Ciencias
[3] Universidad Católica de Temuco,Precision Health Research Laboratory, Departamento de Procesos Diagnósticos y Evaluación, Facultad de Ciencias de La Salud
[4] University of Roehampton,Department of Life Sciences, Whitelands College
[5] University of Sao Paulo,Department of Biochemical and Pharmaceutical Technology, School of Pharmaceutical Sciences
来源
Medical Oncology | / 40卷
关键词
Acute lymphoblastic leukemia; Asparaginase; Antineoplastic agent; Immunogenicity; Hypersensitivity;
D O I
暂无
中图分类号
学科分类号
摘要
l-Asparaginase is an antileukemic drug long approved for clinical use to treat childhood acute lymphoblastic leukemia, the most common cancer in this population worldwide. However, the efficacy and its use as a drug have been subject to debate due to the variety of adverse effects that patients treated with it present, as well as the prompt elimination in plasma, the need for multiple administrations, and high rates of allergic reactions. For this reason, the search for new, less immunogenic variants has long been the subject of study. This review presents the main aspects of the l-asparaginase enzyme from a structural, pharmacological, and clinical point of view, from the perspective of its use in chemotherapy protocols in conjunction with other drugs in the different treatment phases.
引用
收藏
相关论文
共 334 条
[1]  
Lins MM(2017)Incidence and survival of childhood leukemia in Recife, Brazil: A population-based analysis Pediatr Blood Cancer 64 1-6
[2]  
Santos MO(2015)Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden Cancer Causes Control 26 1627-1642
[3]  
de Albuquerque MFPM(2009)Acute Lymphoblastic Leukemia Hematol Oncol Clin North Am 23 655-674
[4]  
de Castro CCL(2019)What makes a good new therapeutic World J Microbiol Biotechnol 35 1-13
[5]  
Mello MJG(1998)-asparaginase? Crit Rev Oncol Hematol 28 97-113
[6]  
de Camargo B(2006)Use of Int J Nanomed 1 241-54
[7]  
Katz AJ(2016)-asparaginase in childhood ALL Appl Biochem Biotechnol 178 900-923
[8]  
Chia VM(2003)Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia Acta Crystallogr Sect D 59 84-92
[9]  
Schoonen WM(2012)A comprehensive review on Appl Biochem Biotechnol 167 2144-2159
[10]  
Kelsh MA(1993)-asparaginase and its applications Proc Natl Acad Sci U S A 90 1474-1478